Organisation paid for research Program year 2024 Source: CMS Open Payments

Rules Based Medicine, Incorporated

Neither a doctor nor a teaching hospital

Research payments

$627,422

9 payments

Through program year 2024, Rules Based Medicine, Incorporated is reported as receiving $627,422 in research payments, across 9 payments.

By program year

3 rows

Year	Kind	Amount	Payments
2024	Research	$138,576	4
2023	Research	$478,963	4
2022	Research	$9,883	1

Breakdown

Who paid Research payments · program years 2022–2024

E.R. Squibb & Sons, L.L.C. $509,407 4 payments
Celgene Corporation $118,015 5 payments

Studies the money was for Research payments · program years 2022–2024

SAD/MAD/FE/FB - A Phase 1, Randomized, Multi-Part, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Doses of BMS-986421 in Healthy Participants $207,447 1 payment
SAD Cohorts - A Phase 1 Randomized, Double-blind, Placebo-controlled, First-in-human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single, Ascending Doses of BMS-986447 in Healthy Adult Participants $190,877 1 payment
A Study to Evaluate the Safety, Tolerability and Drug Levels of BMS-986447 in Healthy Participants $107,423 1 payment
Clin Pharm SAD/FE Study - A Phase 1, Two-part Study to Evaluate the Pharmacokinetics, and Pharmacodynamics of Single Ascending Doses of BMS-986369 and to Explore the Effect of Food the Bioavailability of BMS-986369 in Healthy Participants $67,973 1 payment
Phase 1 DDI (MTX/SSZ) Repeat of CP-002 $46,692 3 payments
A Phase 1, First-in-Human Study of BMS-986421 in Healthy Participants $3,661 1 payment
Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CC-99677 in Healthy Adult Japanese Participants. $3,350 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.